Brief: Bioinvent And Transgene Receive Approval From FDA For Bt-001

BioInvent International AB

27/05/2021 07:34

May 27 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT AND TRANSGENE RECEIVE IND APPROVAL FROM THE U.S.
FDA
FOR BT-001, A NOVEL ONCOLYTIC VIRUS FOR THE TREATMENT OF SOLID
TUMORS
    * BIOINVENT AND TRANSGENE RECEIVE IND APPROVAL FROM THE U.S.
FDA
FOR BT-001, A NOVEL ONCOLYTIC VIRUS FOR THE TREATMENT OF SOLID
TUMORS
    * IND WILL ALLOW PATIENTS IN U.S. TO BE ENROLLED INTO
ONGOING
PHASE 1/2A CLINICAL TRIAL OF THIS NOVEL ONCOLYTIC VIRUS BT-001.
BT-001 IS ARMED WITH BOTH A DIFFERENTIATED TREG-DEPLETING HUMAN
RECOMBINANT ANTI-CTLA4 ANTIBODY AND GM-CSF

Source text for Eikon:  ID:nWkrRH7Z8 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))